FDA grants Roche's Avastin Priority Review for certain types of cervical cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Avastin (bevacizumab) plus chemotherapy for the treatment of women with persistent, recurrent or metastatic cervical cancer.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Cervical Cancer | Chemotherapy | Food and Drug Administration (FDA) | Grants | Pharmaceuticals | Women